Exemplis Discimus 2001, 145(2):61-64

Praesent varius consectetuer mauris.

Shandra Linksa, Erisi Telcontarb, Jyzia Solbornea, Looriw Obdrisa, Chuumba Keela, Rangu Rostonia
a National Institute of Internal medicine, Teaching Hospital of Corellia, Republic of Corellia
b 2nd Clinic of Medical Education, Gordin Reach Faculty Hospital, Kashyyyk Republic

Etiam a lorem consequat velit faucibus accumsan. Aliquam sit amet dolor eu nulla eleifend tempus. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Ut lectus metus, mattis ac, fermentum et, fermentum a, risus. Quisque purus ante, luctus eget, tincidunt et, dapibus sit amet, lacus. Cras eget lacus vel ante adipiscing posuere.. Praesent erat quam, pulvinar id, vulputate eu, pretium et, sapien. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.

Kľúčové slová: Proin sit amet sem, Duis mi, Nulla mattis

Vložený: January 10, 2002; Uverejnené: December 1, 2001 

Zobraziť celý článok

Referencie

  1. Shalhoub, V., Faust, J., Boyle, W. J. et al. (1999) Osteoprotegerin and osteoprotegerin ligand Effects on Osteoclasts formation from human peripheral blood mononuclear cell precursors. J. Cell. Biochem., 72, 251-261. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  2. Browner, W. B., Li-Yang, Lui, Cummingsa, S. R. (2001) Associations of Serum Osteoprotegerin Levels With Diabetes, Stroke, Bone density, fractures and mortality in Elderly Women. The J. of Clin. Endocrinology and Metabolism, 86, 631-637. Prejsť k pôvodnému zdroju...
  3. Zhang, Y., Heulsmann, A., Tondravi, M. M. (2001) TNF-alpha Stimulates RANKL-inducer osteoclastogenesis via coupling of TNF type 1 receptor and RANK Signaling Pathways. J. Biol. Chem., 276, 563-568. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  4. Hofbauer, L. C., Gori, F., Riggs, B. L. et al. (1999) Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucorticoids ih human osteoblastic lineage cells. Endocrinology, 140, 4282-4289. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  5. Hofbauer, L. C., Khosla, S., Dunstan, C. R. et al. (1999) Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology, 14, 4367-4370. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  6. Kaneda, T., Nojima, T., Nakagawa, M. (2000) Endogenous production of TGF-beta is essential for osteoclastogenesis induced by a combination of receptor activator of NF-kappa B ligand and macrophage-colony-stimulating factor. J. Immunol., 165, 4254-4263. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  7. Haltner, W. J.: The effect of a single dose of osteoprotegerin in postmenopausal women. J. Bone. Res., 16, 348-360.
  8. Aubin, J. E., Bonnelye, E. (2000) Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption. Osteoporos. Int., 11, 905-13. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  9. Kostenuik, P. J., Shalhoub, V. (2001) Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. Curr. Pharm. Des., 7, 613-35. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  10. Suda, T., Takahashi, N., Udagawa, N., Jimi, E., Gillespie, M. T., Martin, T. J. (1999) Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev., 3, 345-57. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  11. Haynes, D. R., Crotti, T. N., Potter, A. E., Loric, M., Atkins, G. J., Howie, D. W., Findlay, D. M. (2001) The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis. J. Bone. Joint. Surg. Br., 6, 902-11. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  12. Hofbauer, L. C., Neubauer, A., Heufelder, A. E. (2001) Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. Cancer, 92, 460-70. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  13. Chikazu, D., Katagiri, M., Ogasawara, T., Ogata, N., Shimoaka, T., Takato, T., Nakamura, K., Kawaguchi, H. (2001) Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/ osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors. J. Bone. Miner. Res., 11, 2074-81. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  14. Yano, K., Nakagawa, N., Yasuda, H., Tsuda, E., Higashio, K. (2001) Synovial cells from a patient with rheumatoid arthritis produce osteoclastogenesis inhibitory factor/osteoprotegerin: reciprocal regulation of the production by inflammatory cytokines and basic fibroblast growth factor. J. Bone. Miner. Metab., 6, 365-72. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  15. Jung, K., Lein, M., von Hosslin, K., Brux, B., Schnorr, D., Loening, S. A., Sinha, P. (2001) Osteoprotegerin in serum as a novel marker of bone metastatic spread in prostate cancer. Clin. Chem. 11, 2061-3.
  16. Price, P. A., June, H. H., Buckley, J. R., Williamson, M. K. (2001) Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Rev. Invest. Clin., 4, 362-9.
  17. Brown, J. M., Vessella, R. L., Kostenuik, P. J., Dunstan, C. R., Lange, P. H., Corey, E. (2001) Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. Clin. Cancer. Res. 10, 2977-83.
  18. Yano, K., Shibata, O., Mizuno, A., Kobayashi, F., Higashio, K., Morinaga, T., Tsuda, E. (2001) Immunological study on circulating murine osteoprotegerin/osteoclastogenesis inhibitory factor (opg/ocif): possible role of opg/ocif in the prevention of osteoporosis in pregnancy. Biochem. Biophys. Res. Commun., 288, 217-24. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  19. Feuerherm, A. J., Borset, M., Seidel, C., Sundan, A., Leistad, L., Ostensen, M., Faxvaag, A. (2001) Elevated levels of osteoprotegerin (OPG) and hepatocyte growth factor (HGF) in rheumatoid arthritis. Scand. J. Rheumatol., 30, 229-34. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  20. Sato, T., Tominaga, Y., Iwasaki, Y., Kazama, J. J., Shigematsu, T., Inagaki, H., Watanabe, I., Katayama, A., Haba, T., Uchida, K., Fukagawa, M. (2001) Osteoprotegerin levels before and after renal transplantation. Am. J. Kidney Dis., 38, Suppl. 1, 175-7.
  21. Kazama, J. J., Maruyama, H., Gejyo, F. (2001) Osteoclastogenesis and osteoclast activation in dialysis-related amyloid osteopathy. Am. J. Kidney Dis., 38, Suppl. 1, 156-60.
  22. Seidel, C., Hjertner, O., Abildgaard, N., Heickendorff, L., Hjorth, M., Westin, J., Nielsen (2001) Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood 98, 2269-71. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  23. Kostenuik, P. J., Capparelli, C., Morony, S., Adamu, S., Shimamoto, G., Shen, V., Lacey, D. L., Dunstan, C. R. (2001) OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. Endocrinology, 142, 4295-304. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  24. Pearse, R. N., Sordillo, E. M., Yaccoby, S., Wong, B. R., Liau, D. F., Colman, N., Michaeli, J., Epstein J., Choi, Y. (2001) Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc. Natl. Acad. Sci. U. S. A., 98, 11581-6. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  25. Tintut, Y., Demer, L. L. (2001) Recent advances in multifactorial regulation of vascular calcification. Curr. Opin. Lipidol., 12, 555-60. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  26. McCauley, L. K. (2001) Transgenic mouse models of metabolic bone disease. Curr. Opin. Rheumatol., 13, 316-25. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  27. Ma, Y. L., Cain, R. L., Halladay, D. L., Yang, X., Zeng, Q., Miles, R. R., Chandrasekhar, S., Martin, T. J., Onyia, J. E. (2001) Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology, 142, 4047-54. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  28. Hofbauer, L. C., Heufelder, A. E. (2001) Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. J. Mol. Med., 79, 243-53. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  29. Thirunavukkarasu, K., Miles, R. R., Halladay, D. L., Yang, X., Galvin, R. J., Chandrasekhar, S., Martin, T. J., Onyia, J. E. (2001) Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-beta (TGF-beta). Mapping of the OPG promoter region that mediates TGF-beta effects. J. Biol. Chem., 276, 36241-50. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  30. Corisdeo, S., Gyda, M., Zaidi, M., Moonga, B. S., Troen, B. R. (2001) New insights into the regulation of cathepsin K gene expression by osteoprotegerin ligand. Biochem. Biophys. Res. Commun., 285, 335-9. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  31. Szulc, P., Hofbauer, L. C., Heufelder, A. E., Roth, S., Delmas, P. D. (2001) Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status. J. Clin. Endocrinol. Metab., 86, 3162-5. Prejsť k pôvodnému zdroju... Prejsť na PubMed...
  32. Morony, S., Capparelli, C., Sarosi, I., Lacey, D. L., Dunstan, C. R., Kostenuik, P. J. (2001) Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer. Res., 61, 4432-6. Prejsť na PubMed...

Späť na obsah